A Bioequivalence study of a randomized, open-label, single dose, fully replicated crossover design with four-period, two-treatment, and two-sequence of Dabigatran Etexilate capsules 150 mg relative to PRADAXA 150 MG in healthy Thai volunteers under fasting condition.

Authors
Category Primary study
Registry of TrialsThai Clinical Trials Registry
Year 2024
This article has no abstract
Epistemonikos ID: 63b1a4a5aa999b70a891db827eb15eefac15030d
First added on: Apr 11, 2025